Embrace(TM) Hydrogel Embolic System
Instylla, Inc. · Decision date Aug 5, 2025
What did the FDA approve?
FDA approved the Embrace Hydrogel Embolic System from Instylla, Inc. on August 5, 2025 under PMA number P250003. The approval statement describes the device as indicated for embolization of hypervascular tumors in peripheral arteries of 5 mm or larger.
The record identifies the product code QVG and the specialty Cardiovascular, with the device category listed as Embolization Agent, Vascular. No supplement type or supplement reason is present, so the record does not state whether this decision relates to an original PMA or a later change. The statement reports an intended use only; it does not provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
The Embrace Hydrogel Embolic System (HES) is indicated for embolization of hypervascular tumors in peripheral arteries ? 5mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 5, 2025
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250003
- Regulatory pathway
- Premarket approval application
- Applicant
- Instylla, Inc.
- Product code
- QVG
- Decision code
- APPR
- Decision date
- Aug 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Instylla, Inc.
- Product code
- QVG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250003 received
Application receipt date recorded by FDA.
P250003 · FDA decision
APPR
P250003/S009 · Related supplement
Embrace Hydrogel Embolic System
P250003/S010 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S008 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S011 · Related supplement
Embrace Hydrogel Embolic System
Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Embrace Hydrogel Embolic SystemP250003/S009 | Instylla, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S010 | Instylla, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S008 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Instylla, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

